Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.38 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.35 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30266539 | 1.00 | ERN1 (0.53) | ERN1MEN1LMNATHRBBLM | |
| Ammonia Solution, Strong SCHEMBL28175031 | 0.98 | ERN1 (0.52) | ERN1MEN1LMNATHRBBLM | |
| SCHEMBL6854207 | 0.87 | MEN1 (0.50) | ERN1MEN1LMNATHRBBLM | |
| SCHEMBL24105825 | 0.84 | ERN1 (0.50) | ERN1MEN1LMNATHRBBLM | |
| SCHEMBL30116838 | 0.84 | ERN1 (0.50) | ERN1MEN1LMNATHRBBLM | |
| SCHEMBL25532595 | 0.82 | ERN1 (0.52) | ERN1MEN1LMNATHRBBLM | |
| SCHEMBL1600817 | 0.79 | PIM1 (0.43) | ERN1MEN1LMNATHRBBLM | |
| SCHEMBL28332824 | 0.79 | NFE2L2 (0.38) | ERN1NFE2L2HCAR1TRPA1ALDH1A1 | |
| SCHEMBL11409545 | 0.78 | ALDH1A1 (0.54) | ERN1MEN1LMNATHRBBLM | |
| SCHEMBL2451187 | 0.78 | ALDH1A1 (0.45) | ERN1MEN1LMNATHRBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304594-A1 | METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-4,5,6,7-TETRAHYDRO-1H-CYCLOPENTA[B]PYRIDINE-3-CARBOXYLATE AND METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-1,4,5,7-TETRAHYDROFURO[3,4-B]PYRIDINE-3-CARBOXYLATE AS Cav1,2 ACTIVATORS | NOVARTIS AG (CH) | 2025-10-02 | — | — | US | disclosed |
| US-20250243183-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2025-07-31 | — | — | US | disclosed |
| US-12365690-B2 | Methyl (R)-2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta[B]pyridine-3-carboxylate and methyl 2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyrodine-3-carboxylate as Cav1.2 activators | NOVARTIS AG (CH) | 2025-07-22 | — | — | US | disclosed |
| US-12312331-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2025-05-27 | — | — | US | disclosed |
| EP-3976617-B1 | FUSED HETEROCYCLIC DERIVATIVES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2025-04-23 | — | — | EP | disclosed |
| US-20250002499-A1 | Methyl 2-(Fluoromethyl)-5-Oxo-4-Phenyl-4,5,6,7-Tetrahydro-1h-Cyclopenta[B]Pyridine-3-Carboxylate And Methyl 2- (Fluoromethyl0-5-Oxo-4-Phenyl-1,4,5,7-Tetrahydrofuro[3,4-B]Purodine-3-Carboxylate As Cav1.2 Activators | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CN) | 2025-01-02 | — | — | US | disclosed |
| US-11919911-B2 | Methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta[b]pyridine-3-carboxylate and methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylate as CAV1.2 activators | NOVARTIS AG (CH) | 2024-03-05 | — | — | US | disclosed |
| CN-116348458-A | Imidazolylpyrimidinylamine compounds as CDK2 inhibitors | 因赛特公司 | 2023-06-27 | — | — | CN | disclosed |
| EP-4165047-A1 | METHYL 2-(FLUOROMETHYL)-5-OXO-4-PHENYL-4,5,6,7-TETRAHYDRO-1H-CYCLOPENTA[B]PYRIDINE-3-CARBOXYLATES AND METHYL 2-(FLUOROMETHYL)-5-OXO-4-PHENYL-1,4,5,7-TETRAHYDROFURO[3,4-B]PYRIDINE-3-CARBOXYLATES AS CAV1.2 ACTIVATORS | Novartis AG (CH) | 2023-04-19 | — | — | EP | disclosed |
| CN-115836076-A | Methyl 2- (fluoromethyl) -5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta [ B ] pyridine-3-carboxylate and methyl 2- (fluoromethyl) -5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro [3,4-B ] pyridine-3-carboxylate as CAV1.2 activators | 诺华股份有限公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-2114906-A1 | NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS | F. Hoffmann-Roche AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-20090240087-A1 | Process for Producing Optically Active Fluorobenzyl Alcohol | CENTRAL GLASS COMPANY, LIMITED (JP) | 2009-09-24 | — | — | US | disclosed |
| WO-2009074487-A1 | INHIBITORS OF STEAROYL-COA DESATURASE | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | WO | disclosed |
| US-20090149466-A1 | INHIBITORS OF STEAROYL-COA DESATURASE | GILLESPIE PAUL | 2009-06-11 | — | — | US | disclosed |
| US-20080261920-A1 | 2-Aminooxazolines as TAAR1 ligands | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-23 | — | — | US | disclosed |
| WO-2008092785-A1 | NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-07 | — | — | WO | disclosed |
| EP-1935866-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE FLUOROBENZYL ALCOHOL | Central Glass Company, Limited (JP) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007076835-A1 | METHOD FOR PRODUCTION OF $G(A),$G(B)-UNSATURATED CARBOXYLATE DERIVATIVES | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2007-07-12 | — | — | WO | disclosed |
| JP-2004149458-A | METHOD FOR PRODUCING FLUORO(TRIFLUOROMETHYL)CINNAMIC ACID | CENTRAL GLASS CO LTD | 2004-05-27 | — | — | JP | disclosed |
| WO-2004039760-A1 | PROCESS FOR PRODUCTION OF FLUORO(TRIFLUOROMETHYL)- CINNAMIC ACID | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240087-A1 | Process for Producing Optically Active Fluorobenzyl Alcohol | ADH1A, ADH1C, ADH5 | ERN1 2561/4885MEN1 381/4885LMNA 1625/4885 |
| US-20250002499-A1 | Methyl 2-(Fluoromethyl)-5-Oxo-4-Phenyl-4,5,6,7-Tetrahydro-1h-Cyclopenta[B]Pyridine-3-Carboxylate And Methyl 2- (Fluoromethyl0-5-Oxo-4-Phenyl-1,4,5,7-Tetrahydrofuro[3,4-B]Purodine-3-Carboxylate As Cav1.2 Activators | RYR2, CACNA1D, CACNA1S | ERN1 4626/4885MEN1 2934/4885LMNA 1564/4885 |
| US-12312331-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | CDK2, CDK4, CDK2AP2 | ERN1 703/4885MEN1 2497/4885LMNA 2153/4885 |
| US-20090149466-A1 | INHIBITORS OF STEAROYL-COA DESATURASE | SCD, SCD5, FADS2 | ERN1 2423/4885MEN1 4834/4885LMNA 2327/4885 |
| US-20250304594-A1 | METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-4,5,6,7-TETRAHYDRO-1H-CYCLOPENTA[B]PYRIDINE-3-CARBOXYLATE AND METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-1,4,5,7-TETRAHYDROFURO[3,4-B]PYRIDINE-3-CARBOXYLATE AS Cav1,2 ACTIVATORS | CACNA1D, CACNA1B, CACNA1S | ERN1 4479/4885MEN1 2858/4885LMNA 1615/4885 |
| US-11919911-B2 | Methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta[b]pyridine-3-carboxylate and methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylate as CAV1.2 activators | CACNA1D, CACNA1B, CACNA1S | ERN1 4479/4885MEN1 2900/4885LMNA 1630/4885 |
| US-20250243183-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK4, CDK2AP2 | ERN1 703/4885MEN1 2497/4885LMNA 2153/4885 |
| US-20080261920-A1 | 2-Aminooxazolines as TAAR1 ligands | TAAR1, TAAR5, NPY2R | ERN1 3566/4885MEN1 1746/4885LMNA 3654/4885 |
| US-12365690-B2 | Methyl (R)-2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta[B]pyridine-3-carboxylate and methyl 2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyrodine-3-carboxylate as Cav1.2 activators | CACNA1D, CACNA1B, KCND2 | ERN1 4290/4885MEN1 2539/4885LMNA 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.